# Query Results

**Query:** accuracy issues in audited data

**Timestamp:** 20251020_025455

**Top K:** 5

**Results Found:** 5

---

## Result 1

**Similarity Score:** 0.3494 | **Semantic:** 0.4992 | **Keyword:** 0.0000 | **Rerank:** -3.5285

**Source:** medires.md

**Chunk ID:** 121

**Content:**

```
2]. Hitachi Data was obtained from [24, 25, 104]. Siemens Healthiness data was obtained from ([8, 28, 29, 30, 31, 32]. Varian data was obtained from [ 33, 34, 35, 36, 37, 38] Accuracy data was obtained from [39-44]. **R &D Expenses and Y-O-Y Growth**
Results are shown in Fig.14 20. **IBA: R &D Expenses**
IBA increased R&D investment by 2.5% (rounded to 3%) in 2021 compared to previous year. This means IBA had $0.038 bn invested in R&D in 2021. In 2020 IBA increased R&D investment by 6% compared to 2019 (R&D investment in 2020= $0.4 bn, R& D investment in 2019=$0.035 bn).
```

---

## Result 2

**Similarity Score:** 0.3705 | **Semantic:** 0.5293 | **Keyword:** 0.0000 | **Rerank:** -3.7061

**Source:** medires.md

**Chunk ID:** 34

**Content:**

```
d Accuracy data
was obtained from [39,40, 41, 42, 43, 44]. **Net sales/revenues and change in sales or revenue**
Results are shown in Fig. 3 -1 3
**IBA Revenues and Y-O-Y Growth**
In case of IBA, Proton therapy Segment made highest revenue contributions toward total group revenue from 2020-2015. IBA proton therapy segment contributions towards revenue were greater than revenue contributions made by Proton Solutions segment of Varian Medical Systems from 2020-2018. IBA proton therapy segment generated USD 0.19, 0.23, 0.17, 0.18 bn in 2021, 2020, 2019 and 2018.
```

---

## Result 3

**Similarity Score:** 0.4144 | **Semantic:** 0.5812 | **Keyword:** 0.0250 | **Rerank:** -3.9860

**Source:** medires.md

**Chunk ID:** 51

**Content:**

```
xcluding Japan and China, iv) Japan and V) china. The total revenue of Accuracy was $ 0.396 bn in 2021. Total revenue was $0.383 bn, $0.42 bn, $ 0.41 bn, $0.38 bn, $0.399bn in 2020, 2019, 2018, 2017 and 2016 respectively. This puts Accuracy at position 4 with respect to revenues against its competitors. In 2021, Accuracy showed 3.4% increase in revenue from 2020. In 2020 Accuracy revenues decreased by 8.6% compared to previous year. In 2019 Accuracy again showed 3.5% increase in revenue from 2018.
```

---

## Result 4

**Similarity Score:** 0.3609 | **Semantic:** 0.5013 | **Keyword:** 0.0333 | **Rerank:** -6.4349

**Source:** medires.md

**Chunk ID:** 119

**Content:**

```
line.org/uploads/articles/1676447513image.png)Table XI
**Table XII: Accuracy Strategies and Policies Accuracy Incorporated**![](https://mediresonline.org/uploads/articles/1676447571image.png)Table XII
 1. **Innovation Activity**
```

---

## Result 5

**Similarity Score:** 0.3786 | **Semantic:** 0.5409 | **Keyword:** 0.0000 | **Rerank:** -6.5597

**Source:** medires.md

**Chunk ID:** 50

**Content:**

```
on in three categories (Americas, EMEA and APAC). From 2020-2017 Americas reported highest revenues, followed by EMEA and APAC. **Accuray revenues and Y-O-Y Growth:**
It has only one segment (Oncology Systems Group) to report and the company does not measure the performances of its individual product lines. Hence revenues and Asset information is displayed by geographic areas [41]. Accuracy reports revenues by geographical regions in 5 regions namely i) Americas, ii) Europe, Middle East, India and Africa, iii) Asia Pacific excluding Japan and China, iv) Japan and V) china.
```

---

